Importance and management of dyslipidemia in the metabolic syndrome

American Journal of the Medical Sciences

Volumn 330, Issue 6, 2005, Pages 295-302

  Menuet, Robert ^a   Lavie, Carl J ^a   Milani, Richard V ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; DOCOSAHEXAENOIC ACID; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN; METFORMIN; MEVINOLIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PHYTOSTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; STANOL ESTER;

ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG SAFETY; DYSLIPIDEMIA; FLUSHING; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; ISCHEMIC HEART DISEASE; LIFESTYLE; LIVER TOXICITY; METABOLIC SYNDROME X; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PARTICLE SIZE; PATHOGENESIS; RECURRENT DISEASE; SIDE EFFECT;

EID: 29244458390     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200512000-00007     Document Type: Conference Paper

References (66)

1. Brewer SM, Grundy HB Jr, Cleeman JI, et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-8.
2. Lindsay RS, Howard BV. Cardiovascular risk associated with the metabolic syndrome. Curr Diab Rep 2004;4:63-8.
3. Richelsen B, Pedersen SB. Associations between different anthropometric measurements of fatness and metabolic risk parameters in non-obese, healthy, middle-aged men. Int J Obes Relat Metab Disord 1995;19:169-74.
4. Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, Executive And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
5. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53.
6. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. Adults. Diabetes Care 2004;27:2444-9.
7. Milani RV, Lavie CJ. Prevalance and profile of metabolic syndrome in patients following acute coronary events and effects of therapeutic lifestyle changes with cardiac rehabilitation. Am J Cardiol 2003;92:50-54.
8. Hanley AJG, Williams K, Stern MP, et al. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care 2002;25:1177-84.
9. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414-9.
10. Lakka H-M, Laaksonen DE, Lakka TA et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-16.
11. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004;110:1245-50.
12. Alexander CM, Landsman PB, Teutsch SM, et al. Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003;52:1210-4.
13. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-28.
14. Bays H, Abate N, Chandalia M. Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia. Future Cardiology 2005;1:39-59.
15. Eckel RH, Yost TJ, Jensen DR. Alterations in lipoprotein lipase in insulin resistance. Int J Obes Relat Metab Disord. 1995;19:S16-S21.
16. Murakami T, Michelagnoli S, Longhi R, et al. Triglycerides are major determinants of cholesterol esterification/transfer and HDL remodeling in human plasma. Arterioscler Thromb Vasc Biol 1995;15:1819-28.
17. Haffner SM, Stern MP, Hazuda HP, et al. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990;263:2893-8.
18. Puchois P, Kandoussi A, Fievet JT, et al. Apolipoprotein A-I containing lipoproteins in coronary artery disease. Atherosclerosis 1987;68:35-40.
19. Huang Y, von Eckardstein A, Wu S, et al. Cholesterol efflux, cholesterol esterification, and cholesteryl ester transfer by LpA-I and LpA-I/A-II in native plasma. Arterioscler Thromb Vasc Biol 1995;15:1412-8.
20. Albers JJ, Aladjem F. Precipitation of 125I-labeled lipoproteins with specific polypeptide antisera: Evidence for two populations with differing polypeptide compositions in human high density lipoproteins. Biochemistry 1971;10:3436-42.
21. Larnarche B, Moorjani S, Cantin B, et al. Associations of HDL 2 and HDL 3 subtractions with ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol. 1997;17:1098-1052.
22. Lamarche B, St-Pierre AC, Ruel IL, et al. A prospective, population-based study of low density lipoprotein particle size as a risk factor for. Can J Cardiol 2001;17:859-65.
23. Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996;276:882-8.
24. Austin MA, King MC, Vranizan KM, et al. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation 1990;82:495-506.
25. Skalen K, Gustafsson M, Rydberg EK, et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002;417:750-4.
26. Iuliano L, Mauriello A, Sbarigia E, et al. Radiolabeled native low-density lipoprotein injected into patients with carotid stenosis accumulates in macrophages of atherosclerotic plaque. Effect of vitamin E supplementation. Circulation 2000;101:1249-54.
27. Hurt-Camejo E, Olsson U, Wiklund O, et al. Cellular consequences of the association of apoB lipoproteins with proteoglycans. Potential contribution to atherogenesis. Arterioscler Thromb Vasc Biol 1997;17:1011-7.
28. Lavie CJ, Milani RV. Cardiac rehabilitation and exercise training programs in metabolic syndrome and diabetes. J Cardiopulm Rehabil 2005;25:59-66.
29. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
30. Tuomilheto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.
31. Ridker PM, Buring JE, Cool NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events. Circulation 2003;107:391-397.
32. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-239.
33. Ballantyne CM, Olsson AG, Cook TJ, et al. for the Scandinavian Simvastatin Survival Study (4S) Group. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001;104:3046-51.
34. Pyorala K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614-20.
35. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 1998;98:2513-9.
36. Sacks FM, Tonkin AM, Craven T, et al. Coronary heart disease in patients with low LDL cholesterol: benefit of pravastatin in diabetics and enhanced role of HDL-cholesterol and triglycerides as risk factors. Circulation 2002;105:1424-8.
37. Bottorff MB. Statin safety: What to know. Am Geriatr Cardiol. 2004;13:34-8.
38. Downs JR, Clearfield M, Weis S, et al. for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22.
39. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-8.
40. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
41. Lavie CJ. Assessment and treatment of lipids in elderly persons. Am J Geriatr Cardiol. 2004;13:29-33.
42. Colhoun HH, Betteridge DJ, Durrington PN, et al. on behalf of the CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicenter randomized placebo-controlled trial. Lancet 2004;364:685-96.
43. Nissen SE, Tuzcu EM, Schoenhagen P, et al. for the REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291:1071-80.
44. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285:1711-8.
45. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
46. Deedwania P, Hunninghake D, Bays H, et al. Effects of rosuvastatin, atorvastatin, simvastatin and pravastatin on atherogenic dyslipidemia in patients with characteristics of the Metabolic Syndrome. Am J Cardiol 2005;95:360-6.
47. Alsheikh-Ali AA, Ambrose SS, Kuvin JT, et al. The safety of rosuvastatin as used in common clinical practice: a post-marketing analysis. Circulation 2005;111:3051-7.
48. Lavie CJ. Treatment of hyperlipidemia in elderly persons with exercise training, nonpharmacologic therapy, and drug combinations. Am J Geriatr Cardiol. 2004;13:29-33.
49. Grundy SM. Alternative approaches to lipid-lowering therapy. Am J Cardiol 2002;90:1135-8.
50. Milani RV, Lavie CJ. Lipid lowering drugs: gemfibrozil. In: Meserli FH, editor. Cardiovascular drug therapy. 2nd ed. Philadelaphia, PA: W.B. Saunders Co.;1996; p. 1098-101.
51. Manninen V, Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988;260:641-51.
52. Bloomfield H, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterlol. N Engl J Med 1999;341:410-8.
53. Lavie CJ, Milani RV. Lipid lowering drugs: Nicotinic acid. In: Meserli FH, ed. Cardiovascular Drug Therapy. 2nd ed. Philadelaphia, PA: W.B. Saunders Co. 1996;1061-7.
54. Lavie CJ, Mailander L, Milani RV. Marked benefit with sustained-release niacin therapy in patients with "isolated" very low levels of high-density lipoprotein cholesterol and coronary artery disease. Am J Cardiol 1992;69:1083-5.
55. Bays HE, McGovern ME. Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvostatin and simvastatin. Prev Cardiol 2003;6:179-188.
56. Canner PI, Berge KG, Wenger NK, et al. Fifteen-year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55.
57. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm ischaemic heart disease secondary prevention study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988;223:405-18.
58. Lavie CJ, Milani RV. Niacin in patients with diabetes mellitus and coronary artery disease. Am J Cardiol 2001;87:1137-8.
59. Elam MB, Hunninghake DB, Davis KB, et al. for the ADMIT Investigators. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: The ADMIT Study: A Randomized Trial. JAMA 2000;284:1263-70.
60. Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial. Arch Intern Med 2002;162:156-876.
61. Canner PL, Furberg CD, Terrin ML, et al. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 2005;95:254-7.
62. Levy DA, Pearson TA. Combination niacin and statin therapy in primary and secondary prevention of cardiovascular disease. Clin Cardiol 2005;28:317-20.
63. Ballatyne CM, Houri J, Notarbartolo A, et al. Effects of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003;107:2409-15.
64. Sager PT, Melani L, Lipka L, et al. Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol 2003;92:1414-8.
65. Fichtlscherer S, Schmidt-Lucke C, Roessing L, et al. Short-term statin therapy, but not lipid-lowering with ezitimibe, improves endothelial function in patients with CAD: clinical evidence for the relevance of pleiotropic effects of statins. Circulation 2004;110:374:II-80.
66. Abuissa H, O'Keefe JH Jr, Harris W, et al. Autonomic function, omega-3, and cardiovascular risk. [editorial] Chest 2005;127:1088-91.